

Product Description

Pioneering GTPase and Oncogene Product Development since 2010

CERS5 RABBIT PAB

货号: S220670

产品全名: CERS5 兔多抗 基因符号 Trh4; LASS5

UNIPROT ID: Q8N5B7 (Gene Accession - NP_671723)

背景: This gene encodes a protein that belongs to the TLC (TRAM, LAG1 and CLN8 homology domains) family of proteins. The encoded protein functions in the synthesis of ceramide, a lipid molecule that is involved in a several cellular signaling pathways. Alternate splicing results

in multiple transcript variants.

抗原: Synthetic peptide of human CERS5

经过测试的应用: ELISA, WB, IHC

推荐稀释比: IHC: 50-200;WB: 200-1000;ELISA: 1000-2000

种属反应性: Rabbit

克隆性: Rabbit Polyclonal

亚型: Immunogen-specific rabbit IgG 纯化: Antigen affinity purification 种属反应性: Human, Mouse

成分: PBS (without Mg2+ and Ca2+), pH 7.4, 150 mM NaCl, 0.05% Sodium Azide and 40% glycerol


研究领域: Metabolism, Cancer

储存和运输: Store at -20°C. Avoid repeated freezing and thawing




Product Description


Pioneering GTPase and Oncogene Product Development since 2010




cancer tissue using 220670(CERS5 Antibody) at a dilution of 1/35(Cytoplasm or Nucleus).




Immunohistochemistry analysis of paraffin embedded Human colon In comparision with the IHC on the left, the same paraffin-embedded Human colon cancer tissue is first treated with the synthetic peptide and then with 220670(Anti-CERS5 Antibody) at dilution 1/35.



The image on the left is immunohistochemistry of paraffinembedded Human cervical cancer tissue using 220670(Anti-CERS5 Antibody) at a dilution of 1/35.



In comparision with the IHC on the left, the same paraffin-embedded Human cervical cancer tissue is first treated with synthetic peptide and then with D261850(Anti-CERS5 Antibody) at dilution 1/35.



Gel: 8%SDS-PAGE, Lysate: 40 µg; Lane: Human fetal brain tissue; Primary antibody: 220670 (CERS5 Antibody) at dilution 1/350; Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution; Exposure time: 5 minutes



Product Description

Pioneering GTPase and Oncogene Product Development since 2010